CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Tumour microenvironment and heterotypic interactions in pancreatic cancer.
Tumour microenvironment and heterotypic interactions in pancreatic cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胰腺导管腺癌（PDA）是一种生存率为9%的疾病；这是由于其对化疗的耐药性以及占据大部分肿瘤体积的巨大肿瘤间质。它由大量免疫系统细胞组成，如Treg细胞、肿瘤相关巨噬细胞（TAMs）、髓系抑制细胞（MDCs）和肿瘤相关中性粒细胞（TANs），这些细胞通过释放炎性细胞因子产生免疫抑制环境。此外，癌相关成纤维细胞（CAFs）提供保护性覆盖，使化疗难以进入肿瘤。据此，应开发能够重塑这种异质性肿瘤微环境的新疗法，如过继性T细胞疗法（ACT）、免疫检查点抑制剂（ICI）和CD40激动剂，以靶向PDA。本综述整理了肿瘤间质中参与肿瘤进展的不同细胞群体，以及正在研究的用于对抗肿瘤的不同疗法。
Pancreatic ductal adenocarcinoma (PDA) is a disease with a survival rate of 9%; this is due to its chemoresistance and the large tumour stroma that occupies most of the tumour mass. It is composed of a large number of cells of the immune system, such as Treg cells, tumour-associated macrophages (TAMs), myeloid suppressor cells (MDCs) and tumour-associated neutrophiles (TANs) that generate an immunosuppressive environment by the release of inflammatory cytokines.
Moreover, cancer-associated fibroblast (CAFs) provide a protective coverage that would difficult the access of chemotherapy to the tumour. According to this, new therapies that could remodel this heterogeneous tumour microenvironment, such as adoptive T cell therapies (ACT), immune checkpoint inhibitors (ICI), and CD40 agonists, should be developed for targeting PDA.
This review organizes the different cell populations found in the tumour stroma involved in tumour progression in addition to the different therapies that are being studied to counteract the tumour.
MEMBER ACCOUNT
登录成功会直接打开下一页。
